These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16272774)

  • 21. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: a 4 year follow-up study.
    Fadul JE; Vessby B; Wikström B; Danielson BG
    Artif Organs; 1997 May; 21(5):364-8. PubMed ID: 9129767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of severe hypercholesterolemia by LDL-apheresis: cholesterol-lowering effect and clinical evaluation.
    Saito Y; Shinomiya M; Shirai K; Yoshida S
    Beitr Infusionsther; 1988; 23():160-71. PubMed ID: 2484772
    [No Abstract]   [Full Text] [Related]  

  • 24. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).
    Aengevaeren WR; Kroon AA; Stalenhoef AF; Uijen GJ; van der Werf T
    J Am Coll Cardiol; 1996 Dec; 28(7):1696-704. PubMed ID: 8962554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term effect of LDL apheresis on coronary heart disease.
    Donner MG; Richter WO; Schwandt P
    Eur J Med Res; 1997 Jun; 2(6):270-4. PubMed ID: 9182655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators.
    Tatami R; Inoue N; Itoh H; Kishino B; Koga N; Nakashima Y; Nishide T; Okamura K; Saito Y; Teramoto T
    Atherosclerosis; 1992 Jul; 95(1):1-13. PubMed ID: 1642687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia.
    Mabuchi H; Higashikata T; Kawashiri MA
    Transfus Apher Sci; 2004 Jun; 30(3):233-43. PubMed ID: 15172629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group.
    Gordon BR; Kelsey SF; Dau PC; Gotto AM; Graham K; Illingworth DR; Isaacsohn J; Jones PH; Leitman SF; Saal SD; Stein EA; Stern TN; Troendle A; Zwiener RJ
    Am J Cardiol; 1998 Feb; 81(4):407-11. PubMed ID: 9485128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures.
    Fukuzawa S; Ozawa S; Inagaki M; Morooka S; Inoue T
    Intern Med; 1999 Apr; 38(4):330-5. PubMed ID: 10361905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
    Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of heterozygous familial hypercholesterolemia showing the regression of coronary atherosclerosis by LDL-apheresis].
    Nomura S; Kouzuma R; Komura T; Sadayasu T; Segawa J; Nakashima Y; Kuroiwa A
    Kokyu To Junkan; 1992 Mar; 40(3):299-302. PubMed ID: 1579754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia.
    Koga N; Iwata Y
    Atherosclerosis; 1991 Sep; 90(1):9-21. PubMed ID: 1799400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
    Zwiener RJ; Uauy R; Petruska ML; Huet BA
    J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of LDL-apheresis on the long-term prognosis of hypercholesterolemic patients with coronary artery bypass grafts: a multicenter study].
    Kito Y; Takahashi J; Endo M; Agishi T; Kitamura S; Matsuda H; Fujiwara T; Dohi T; Ito T; Kawashima Y
    Kyobu Geka; 1993 May; 46(5):399-404. PubMed ID: 8492490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Olbricht CJ; Schoeppe E
    Ther Apher; 1997 Aug; 1(3):242-8. PubMed ID: 10225746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia.
    Vella A; Pineda AA; O'Brien T
    Mayo Clin Proc; 2001 Oct; 76(10):1039-46. PubMed ID: 11605688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
    Kroon AA; van Asten WN; Stalenhoef AF
    Ann Intern Med; 1996 Dec; 125(12):945-54. PubMed ID: 8967704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.